Overall, the low-grade group had significantly higher FOXO3a scores than the moderate-grade and the high-grade subgroups (Figure 5B), suggesting that FOXO3a may gradually lose its function along with the progression of prostate cancer. This evidence concerns the gene FOXO3 and prostate cancer.